ArticleJournal of personalized medicine2025

Real-Life Treatment Intervals and Morphological Outcomes Following the Switch to Faricimab Therapy in Neovascular Age-Related Macular Degeneration.

Katrin Löw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.